Hyaluronidase (Human Recombinant)
drug drugOn this page
Also known as ChemophaseCumulaseEnhanzeHuman hyaluronidaseHyaluronidase (human)Hyaluronidase fihjHyaluronidase human recombinantHyaluronidase oyskHyaluronidase recombinant humanHyaluronidase zzxfHyaluronidasehumanhuman recombinantHyaluronidase-fihjHyaluronidase-ocsqHyaluronidase-oyskHyaluronidase-qvfcHyaluronidase-tqjcHyaluronidase-zzxf
Summary
Hyaluronidase (Human Recombinant) (CHEMBL1201718) is an approved enzyme; indicated across 22 conditions including plasma cell myeloma and chronic inflammatory demyelinating polyradiculoneuropathy.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Enzyme
- Indications: 22 conditions
- Clinical trials: 64
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201718 |
| Name | Hyaluronidase (Human Recombinant) |
| Type | Enzyme |
| Max phase | 4 |
Also known as: Chemophase, Cumulase, Enhanze, Human hyaluronidase, Hyaluronidase (human recombinant), Hyaluronidase (human), Hyaluronidase fihj, Hyaluronidase human recombinant, Hyaluronidase oysk, Hyaluronidase recombinant human, Hyaluronidase zzxf, Hyaluronidase
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
17 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| plasma cell myeloma | 3 | MONDO:0009693 | EFO:0001378 |
| chronic inflammatory demyelinating polyradiculoneuropathy | 3 | MONDO:0006702 | EFO:1000868 |
| non-small cell lung carcinoma | 3 | MONDO:0005233 | EFO:0003060 |
| clear cell renal carcinoma | 3 | MONDO:0005005 | EFO:0000349 |
| melanoma | 3 | MONDO:0005105 | EFO:0000756 |
| smoldering plasma cell myeloma | 3 | MONDO:0005235 | EFO:0003073 |
| psoriasis | 2 | MONDO:0005083 | EFO:0000676 |
| allergic contact dermatitis | 2 | MONDO:0006525 | EFO:1000668 |
| HIV infectious disease | 2 | MONDO:0005109 | EFO:0000764 |
| type 1 diabetes mellitus | 2 | MONDO:0005147 | MONDO:0005147 |
| type 2 diabetes mellitus | 2 | MONDO:0005148 | MONDO:0005148 |
| hereditary angioedema | 2 | MONDO:0019623 | MONDO:0019623 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| diabetes mellitus | 1 | MONDO:0005015 | EFO:0000400 |
| osteoporosis | 1 | MONDO:0005298 | EFO:0003882 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| multiple sclerosis | 1 | MONDO:0005301 | MONDO:0005301 |
5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 64.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 24 |
| PHASE2 | 14 |
| PHASE3 | 11 |
| PHASE1/PHASE2 | 7 |
| PHASE4 | 4 |
| Not specified | 3 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00311519 | PHASE4 | COMPLETED | A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects |
| NCT00477152 | PHASE4 | COMPLETED | Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children |
| NCT01139294 | PHASE4 | COMPLETED | Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics |
| NCT05511428 | PHASE4 | COMPLETED | Home Based Daratumumab Administration for Patients With Multiple Myeloma |
| NCT03301220 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma |
| NCT04071457 | PHASE3 | ACTIVE_NOT_RECRUITING | S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration |
| NCT04566328 | PHASE3 | RECRUITING | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial |
| NCT04810078 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread |
| NCT05256225 | PHASE3 | RECRUITING | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma |
| NCT05561387 | PHASE3 | RECRUITING | Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment |
| NCT05625399 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma |
| NCT06022939 | PHASE3 | RECRUITING | Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis |
| NCT00593281 | PHASE3 | COMPLETED | INFUSE Morphine Study |
| NCT03735121 | PHASE3 | COMPLETED | A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| NCT05297565 | PHASE3 | COMPLETED | A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection |
| NCT05020860 | PHASE2 | RECRUITING | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer |
| NCT05300451 | PHASE2 | ENROLLING_BY_INVITATION | Daratumumab in HLA Desensitization Prior to Transplantation |
| NCT05996471 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) |
| NCT06100874 | PHASE2 | ACTIVE_NOT_RECRUITING | A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) |
| NCT06101134 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations |
| NCT06697197 | PHASE1/PHASE2 | RECRUITING | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors |
| NCT07110844 | PHASE2 | RECRUITING | Teclistamab-Daratumumab in AL Amyloidosis |
| NCT07247097 | PHASE2 | NOT_YET_RECRUITING | ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma |
| NCT00318643 | PHASE1/PHASE2 | COMPLETED | Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer |
| NCT00928447 | PHASE2 | COMPLETED | Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis |
| NCT01987609 | PHASE2 | COMPLETED | Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques |
| NCT02754141 | PHASE1/PHASE2 | COMPLETED | An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab |
| NCT03446040 | PHASE1/PHASE2 | TERMINATED | An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread |
| NCT03656718 | PHASE1/PHASE2 | COMPLETED | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) |
| NCT04632992 | PHASE2 | COMPLETED | A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response |
| NCT04776018 | PHASE1/PHASE2 | TERMINATED | A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) |
| NCT05205252 | PHASE1/PHASE2 | WITHDRAWN | A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. |
| NCT05496192 | PHASE2 | WITHDRAWN | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer |
| NCT05730712 | PHASE2 | COMPLETED | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer |
| NCT05807048 | PHASE2 | COMPLETED | Daratumumab in STK11 Mutated NSCLC |
| NCT06046287 | PHASE2 | WITHDRAWN | Daratumumab for Polyneuropathy Associated With MGUS |
| NCT05139225 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma |
| NCT05418868 | PHASE1 | RECRUITING | A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants |
| NCT06310551 | PHASE1 | RECRUITING | First Time in Human Study of Long Acting VH4524184 Formulations |
| NCT00435604 | PHASE1 | COMPLETED | A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase |
| NCT00782587 | PHASE1 | COMPLETED | Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer |
| NCT00803972 | PHASE1 | COMPLETED | Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20 |
| NCT00807963 | PHASE1 | COMPLETED | Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone |
| NCT00862849 | PHASE1 | COMPLETED | Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone |
| NCT01572012 | PHASE1 | COMPLETED | Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers |
| NCT02654522 | PHASE1 | COMPLETED | The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers |
| NCT03320707 | PHASE1 | COMPLETED | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants |
| NCT03538626 | PHASE1 | COMPLETED | Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) |
| NCT03972306 | PHASE1 | COMPLETED | A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis |
| NCT04045028 | PHASE1 | TERMINATED | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
| NCT04112498 | PHASE1 | COMPLETED | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab |
| NCT04311710 | PHASE1 | TERMINATED | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types |
| NCT04532125 | PHASE1 | COMPLETED | SAD and MAD Study With IV and SC Doses of ARGX-117 |
| NCT04714372 | PHASE1 | COMPLETED | FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia |
| NCT04920370 | PHASE1 | COMPLETED | Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects |
| NCT04956302 | PHASE1 | TERMINATED | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma |
| NCT05291520 | PHASE1 | COMPLETED | A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants |
| NCT05293249 | PHASE1 | COMPLETED | dMAbs for Prevention of COVID-19 |
| NCT05396742 | PHASE1 | COMPLETED | Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers |
| NCT06511570 | PHASE1 | COMPLETED | A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants |
| NCT05238831 | EARLY_PHASE1 | WITHDRAWN | SMMART Adaptive Clinical Treatment (ACT) Trial |
| NCT00547664 | Not specified | COMPLETED | Efficacy of Hylenex in the Treatment of Pain Among Hospice Patients |
| NCT02885259 | Not specified | UNKNOWN | HyQvia in Multifocal Motor Neuropathy |
| NCT03778736 | Not specified | COMPLETED | Using Cumulase for Denudation of Cycles With ≤ 8 Cumulus-oocytes Complexes |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: plasma cell myeloma, chronic inflammatory demyelinating polyradiculoneuropathy, non-small cell lung carcinoma, clear cell renal carcinoma, melanoma, smoldering plasma cell myeloma, psoriasis, allergic contact dermatitis, HIV infectious disease, type 1 diabetes mellitus, type 2 diabetes mellitus, hereditary angioedema, breast neoplasm